Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT04684472
What this trial is testing

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory Leukemia
Liqun Zou 18
Testing effectiveness (Phase 2)Study completedNCT03484702
What this trial is testing

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 113
Very early researchNot Yet RecruitingNCT04609241
What this trial is testing

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed and/or Refractory Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
Zhejiang University 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07122609
What this trial is testing

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed and Refractory DLBCL
Ruijin Hospital 22
Testing effectiveness (Phase 2)Study completedNCT01381692
What this trial is testing

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Who this might be right for
Recurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma+8 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)WithdrawnNCT05929716
What this trial is testing

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaB-cell Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT05515406
What this trial is testing

Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Ono Pharmaceutical Co., Ltd. 9
Testing effectiveness (Phase 2)WithdrawnNCT06005649
What this trial is testing

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Juventas Cell Therapy Ltd.
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Early research (Phase 1)Study completedNCT01897012
What this trial is testing

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Who this might be right for
MYC PositiveRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt Lymphoma+14 more
National Cancer Institute (NCI) 26
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Not applicableStudy completedNCT00049465
What this trial is testing

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

Who this might be right for
Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00089011
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+171 more
Fred Hutchinson Cancer Center 150
Testing effectiveness (Phase 2)Study completedNCT02650999
What this trial is testing

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Who this might be right for
CD19+ Diffuse Large B-cell LymphomasFollicular LymphomasMantle Cell Lymphomas
Abramson Cancer Center at Penn Medicine 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07162571
What this trial is testing

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Who this might be right for
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT06300528
What this trial is testing

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
University of Utah 1
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics Incorporated 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT05563844
What this trial is testing

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B Cell Lymphoma，DLBCL
Chengdu Zenitar Biomedical Technology Co., Ltd 74
Testing effectiveness (Phase 2)Looking for participantsNCT06838832
What this trial is testing

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital 30
Next Page